期刊文献+

皮肤磨削术联合5%咪喹莫特治疗面部光线性角化病临床观察 被引量:2

下载PDF
导出
摘要 目的探讨皮肤磨削术联合5%咪喹莫特治疗面部光线性角化病临床疗效。方法 64例光线性角化病均经组织病理学确诊。治疗组采用皮肤磨削术联合5%咪喹莫特治疗面部光线性角化病;对照组单纯外用5%咪喹莫特治疗面部光线性角化病。结果治疗组有27例完全缓解,5例部分缓解,治疗组疗效明显高于对照组(P<0.05)。结论皮肤磨削术联合5%咪喹莫特治疗面部光线性角化病疗效确切,方法简单,患者耐受性好,很好的保持患者美容,有良好的推广前景。
出处 《中国医学工程》 2015年第1期118-118,120,共2页 China Medical Engineering
  • 相关文献

参考文献5

  • 1赵辨.中国临床皮肤病学[M].第1版.南京:江苏科学技术出版社.2009.1165-1169.
  • 2GiuffrG,Barres iV,Catalano A,et al.A ct in ic keratos is assoc iated with squamous and basal cell carcinoma as an evaluation of neoplastic progression by a standardized AgNOR analysis[J].Eu r JH istochem.2008,52 (1) :53- 60.
  • 3张学军.皮肤性病学[M].7版.北京:人民卫生出版社.2010:175-177.
  • 4Coleman WP 3rd,Yarborough JM,Mandy SH.Dermabrasion for prophylaxis and treatment of actinic keratoses.Dermatol Surg. 1996 Jan;22(1):17-21.
  • 5吴剑波,郑家润.咪喹莫特的实验室与临床研究进展[J].国外医学(皮肤性病学分册),2003,29(2):74-77. 被引量:22

二级参考文献25

  • 1Sauder DN. Immunomodulatory and pharmacologic properties of imi quimod. J Am Acad Dermatol, 2000, 43( 1 Pt 2) :S6 - 11.
  • 2Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S - 28463, using gene expression array analysis. Antimicrob Agents Chemother, 2001,45 (4): 1137 - 1142.
  • 3Bums RP Jr, Ferbel B, Tomai M ,et al. The imidazoquinolines, imiquimod and R -848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol, 2000, 94(1):13-23.
  • 4Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R 848 and imiquimod. Cell Immunol, 1999, 191 ( 1 ) :10 - 19.
  • 5Bishop GA, Ramirez LM, Baccam M, et al. The immune response modifier resiquimod mimics CD40 - induced B cell activation. Cell Immunol, 2001, 208( 1 ) :9 - 17.
  • 6Hemmi H, Kaisho T, Takeuchi O,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88 -dependent signaling pathway. Nat Immunol, 2002, 3 (2): 196 - 200.
  • 7Soria I, Myhre P, Horton V, et al. Effect of food on the pharmacoki netics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther, 2000, 38(10) :476 -481.
  • 8Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and peri anal warts. Prim. Care Update Ob Gyns, 1998, 5(4) :151.
  • 9Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother, 1998, 42(4) :789 -794.
  • 10Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imi quimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis, 1998, 178 (3) :858 - 861.

共引文献49

同被引文献23

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部